NEW YORK STOCK EXCHANGE, INC. · PFE

+0.36% · +$0.1000 · Vol Not reported

Pre-market · updated 05:42:12 ET

Pfizer Inc

Pharmaceuticals

$27.75

Card

Relationship Map

Follow $PFE

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $PFE by email

Veridion Score

BETAHIGH CONF · 6 of 6 factors measured

Thu Sep 10 · last completed session · Pre-market · regular session opens 9:30 ET · PFE

Methodology

PFE

Pfizer Inc

Thu Sep 10 · last completed session · Pre-market · regular session opens 9:30 ET

66/100

Upper range

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

66/ 100

Veridion Score

Upper range · HIGH confidence · 6 of 6 factors measured

Sovereign · $25/mo

See why this score moved.

· Factor breakdown with raw signals
· Day-over-day delta + driver
· Factor coverage readout
· Valuation · hype · market flow
· Pro Chart event markers
· Score history + alerts

Start Sovereign · $25/mo →

Cancel anytime · or Reserve · $79/mo

Confidence: HIGH · 6 of 6 factors measured · Thu Sep 10 · last completed session · Pre-market · regular session opens 9:30 ET

Share on X →

Veridion Score History · 90D

AI Analysis

Sovereign

Why is PFE moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.

Catalyst calendar

What can move PFE next.

Earnings, ratings, disclosures, volume, and score-history events. Every row needs a dated receipt.

Congress / Form 4 / Score

Upcoming

No dated upcoming catalyst is present in the current source window.

Recent

Sep 10
Score
Score moved -11
77/Highest qualified -> 66/Upper range
Veridion score historySource
Aug 12
Form 4Checking access
BOURLA ALBERT Form 4 buy
Checking the receipt access included with your plan.
SEC Form 4Checking access
Aug 6
Form 4Checking access
DAMICO JENNIFER B. Form 4 sale
Checking the receipt access included with your plan.
SEC Form 4Checking access
Aug 5
Form 4Checking access
BLAYLOCK RONALD E Form 4 buy
Checking the receipt access included with your plan.
SEC Form 4Checking access
Aug 5
Form 4Checking access
Buckley Mortimer J Form 4 buy
Checking the receipt access included with your plan.
SEC Form 4Checking access
Jul 7
CongressChecking access
Ro Khanna purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Jun 16
CongressChecking access
Ro Khanna sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Jun 8
CongressChecking access
Tommy Tuberville sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Jun 2
CongressChecking access
Ro Khanna sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
May 15
CongressChecking access
Ro Khanna purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access

About Pfizer Inc

PHARMACEUTICAL PREPARATIONS

Listed since

1951

Employees

75K

Country

Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndamax and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.

Company website →

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open

$27.65

Last session

Day high

$27.65

Last session

Day low

$27.65

Last session

Previous close

$27.65

52W high

$29.02

-4.38% from high

52W low

$23.60

77% of range

Market cap

$157.6B

P/E

36.15×

EPS

$1.56

Beta

0.02

Shares out

5.7B

Avg volume

37.3M

VWAP

$27.65

Last session

Price history computed in-house

-2.46%

+5.47%

+5.88%

+11.63%

YTD

+11.45%

SMA 50 $26.19 · above

SMA 200 $26.21 · above

52W position 77%

PFE overview

Veridion Score

Registered · 2026-09-10

6 of 6 factors measured

Latest receipt rows

Ro Khanna · Purchase

13F holders

Scion Asset Management

Receipt-backed holder profiles

Scion Asset Management · $152.9M Fairholme Capital Management · $5.6M

SEC industry peers

PFE peers

ABBVAbbVie Inc.SEC SIC 2834

ABBV Form 10-K · SEC SIC 2834 · Feb 20, 2026 ↗

BMYBRISTOL MYERS SQUIBB COSEC SIC 2834

BMY Form 10-K · SEC SIC 2834 · Feb 11, 2026 ↗

JNJJOHNSON & JOHNSONSEC SIC 2834

JNJ Form 10-K · SEC SIC 2834 · Feb 11, 2026 ↗

LLYELI LILLY & CoSEC SIC 2834

LLY Form 10-K · SEC SIC 2834 · Feb 12, 2026 ↗

MRKMerck & Co., Inc.SEC SIC 2834

MRK Form 10-K · SEC SIC 2834 · Feb 24, 2026 ↗

Relationship mapTrace receipt-backed holders and filings around PFE.Congress disclosuresOpen receipt and filing context for PFE.MethodologyReview score inputs, coverage rules, and limitations.

SEC Form 4 ledger

PFE insider activity

Pfizer Inc

Score

66 · Upper range

Pressure

Net buying

Filings

Buys / sells

3 / 1

Net value

$2.9M

Insiders

Named filers

BOURLA ALBERT

Director · Chairman & CEO

Board

DAMICO JENNIFER B.

SVP & Controller

Officer

BLAYLOCK RONALD E

Director

Board

Cluster

3 insiders bought in the last 90 days

Net pressure

Net buying: $2.9M across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Scroll across filed transactions. Filing date stays visible.

Filing date	Trade date	Insider	Title	Type	Price	Qty	Owned	Value	Receipt
2026-08-12	2026-08-12	BOURLA ALBERT	Director · Chairman & CEO	buy	$26.34	38,000	429,173	$1.0M	SEC Form 4
2026-08-06	2026-08-05	DAMICO JENNIFER B.	SVP & Controller	sell	$25.40	3,278	28,611	$83K	SEC Form 4
2026-08-05	2026-08-05	BLAYLOCK RONALD E	Director	buy	$25.46	39,231	66,938	$999K	SEC Form 4